CoChat

Next-generation sequencing for BCR-ABL1 kinase domain mutation testing in patients with chronic myeloid leukemia: a position paper

Open access
Soverini, Simona, Abruzzese, Elisabetta, Bocchia, Monica, Bonifacio, Massimiliano, Galimberti, Sara, Gozzini, Antonella, Iurlo, Alessandra, Luciano, Luigiana, Pregno, Patrizia, Rosti, Gianantonio, Saglio, Giuseppe, Stagno, Fabio, Tiribelli, Mario, Vigneri, Paolo, Barosi, Giovanni, Breccia, Massimo · 2019 · Journal of Hematology & Oncology
Cited by 74

The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.

Abstract

BCR-ABL1 kinase domain (KD) mutation status is considered to be an important element of clinical decision algorithms for chronic myeloid leukemia (CML) patients who do not achieve an optimal response to tyrosine kinase inhibitors (TKIs). Conventional Sanger sequencing is the method currently recommended to test BCR-ABL1 KD mutations. However, Sanger sequencing has limited sensitivity and cannot always discriminate between polyclonal and compound mutations. The use of next-generation sequencing (NGS) is increasingly widespread in diagnostic laboratories and represents an attractive alternative. Currently available data on the clinical impact of NGS-based mutational testing in CML patients do not allow recommendations with a high grade of evidence to be prepared. This article reports the results of a group discussion among an ad hoc expert panel with the objective of producing recommendations on the appropriateness of clinical decisions about the indication for NGS, the performance characteristics of NGS platforms, and the therapeutic changes that could be applied based on the use of NGS in CML. Overall, these recommendations might be employed to inform clinicians about the practical use of NGS in CML.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1186/s13045-019-0815-5

Cites

4 of 4 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 4 references

Cited by

See all 74

Metadata

Authors
Soverini, S., Abruzzese, E., Bocchia, M., Bonifacio, M., Galimberti, S., Gozzini, A., Iurlo, A., Luciano, L., Pregno, P., Rosti, G., Saglio, G., Stagno, F., Tiribelli, M., Vigneri, P., Barosi, G., & Breccia, M.
Venue
Journal of Hematology & Oncology
Published
2019-12
Volume
12
Issue
1
Pages
131-131
ISSN
1756-8722 (ISSN-L)
OpenAlex
W2994609811
Cited by
74
References
4
FWCI
5.59
Type
journal article
Language
en
Open access
gold

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Next-generation sequencing for BCR-ABL1 kinase domain mutation testing in patients with chronic myeloid leukemia: a position paper. https://app.cochat.ai/papers/10.1186/s13045-019-0815-5
The paper
Soverini, S., Abruzzese, E., Bocchia, M., Bonifacio, M., Galimberti, S., Gozzini, A., Iurlo, A., Luciano, L., Pregno, P., Rosti, G., Saglio, G., Stagno, F., Tiribelli, M., Vigneri, P., Barosi, G., & Breccia, M. (2019). Next-generation sequencing for BCR-ABL1 kinase domain mutation testing in patients with chronic myeloid leukemia: a position paper. Journal of Hematology & Oncology. https://doi.org/10.1186/s13045-019-0815-5

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.